Jazz JZP926 Phase 2/3 Epilepsy Trial: Recruiting; Actual Start Registered
ClinicalTrials.gov lists NCT07723963 as recruiting, with 2026-09-18 marked as an actual start. Registry update posted 2026-10-06.
This article records evidence available when published or updated. Registration dates are not proof of trial enrollment; check the original sources for current status.
Update, October 21, 2026: The official ClinicalTrials.gov record now lists this study as recruiting. The registry now records 2026-09-18 as the actual study start. The latest registry update was posted 2026-10-06. This update supersedes the recruitment and start-date assessment in our September 23 correction.
What is registered
Jazz Pharmaceuticals registered a Phase 2/3 study of JZP926 against placebo for people with juvenile myoclonic epilepsy. The study record identifies it as NCT07723963 and lists planned enrollment of 260 participants. Enrollment is an estimate in the protocol, not a count of participants already enrolled. The registered design and comparisons describe what investigators intend to test; they do not establish safety, efficacy, or a completed clinical milestone.
Choose a company and prepare a question. Run it manually after confirming the question and reviewing the required credits.
Prepared research question
Jazz JZP926 Phase 2/3 Epilepsy Trial: which company evidence supports or challenges the article?
Traceable citations · Unknowns marked
How to read the current record
The actual start date is a sponsor-reported registry milestone. It does not establish that enrollment is complete, that results are available, or that the treatment is safe or effective. The protocol lists 260 participants as estimated enrollment; this is a target, not the number already enrolled. The registered phase is Phase 2/3.
Recruitment status, estimated completion dates, reported results, and regulatory decisions are distinct milestones. Check the latest official record for subsequent changes before using the trial in a research decision. This article reports the registry fields retrieved on October 21, 2026, rather than a prediction of clinical or investment outcomes.
Follow the evidence
The original article URL is retained so earlier links reach this update. BioSniper's company page provides a starting point for related research; each tracked event still requires its own source and date verification.
Source: ClinicalTrials.gov study NCT07723963, retrieved October 21, 2026. Latest posted update: 2026-10-06.